- Home
- CWST vs GH Comparison
CWST vs GH Comparison
Compare CWST & GH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CWST
- GH
- Stock Information
- Founded
- CWST 1975
- GH 2011
- Country
- CWST United States
- GH United States
- Employees
- CWST N/A
- GH N/A
- Industry
- CWST Environmental Services
- GH Medical Specialities
- Sector
- CWST Utilities
- GH Health Care
- Exchange
- CWST Nasdaq
- GH Nasdaq
- Market Cap
- CWST 5.8B
- GH 4.9B
- IPO Year
- CWST 1997
- GH 2018
- Fundamental
- Price
- CWST $96.72
- GH $108.29
- Analyst Decision
- CWST Strong Buy
- GH Strong Buy
- Analyst Count
- CWST 8
- GH 21
- Target Price
- CWST $119.50
- GH $75.48
- AVG Volume (30 Days)
- CWST 651.9K
- GH 3.6M
- Earning Date
- CWST 10-30-2025
- GH 10-29-2025
- Dividend Yield
- CWST N/A
- GH N/A
- EPS Growth
- CWST 102.54
- GH N/A
- EPS
- CWST 0.24
- GH N/A
- Revenue
- CWST $1,795,272,000.00
- GH $902,569,000.00
- Revenue This Year
- CWST $20.21
- GH $33.95
- Revenue Next Year
- CWST $7.48
- GH $25.77
- P/E Ratio
- CWST $402.48
- GH N/A
- Revenue Growth
- CWST 20.54
- GH 30.38
- 52 Week Low
- CWST $82.22
- GH $29.91
- 52 Week High
- CWST $121.24
- GH $112.43
- Technical
- Relative Strength Index (RSI)
- CWST 69.00
- GH 74.35
- Support Level
- CWST $90.75
- GH $98.23
- Resistance Level
- CWST $95.80
- GH $112.43
- Average True Range (ATR)
- CWST 2.34
- GH 5.58
- MACD
- CWST 1.03
- GH 0.32
- Stochastic Oscillator
- CWST 91.42
- GH 80.42
About CWST Casella Waste Systems Inc.
Casella Waste Systems Inc is a solid waste removal company, providing resource management services to residential, commercial, municipal, and industrial customers. The company's reportable segments on Geographical basis include Eastern, Western and Mid-Atlantic regions through the Resource solution segment. It generates maximum revenue from the Western region segment. The company's services include Recycling, Collection, Organics, Energy, Landfills, Special Waste as well as Professional Services.
About GH Guardant Health Inc.
Guardant Health, Inc, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company offers Guardant360 LDT, a liquid biopsy test for treatment selection in advanced stage cancer, Guardant360 CDx, an FDA-approved companion diagnostic for several targeted therapies, and Guardant OMNI, a broader gene panel for immuno-oncology research. In 2021, Guardant launched Reveal, a tumor-agnostic molecular residual disease, or MRD, test. In 2024, the company received US FDA approval for Shield, a liquid biopsy for colorectal cancer, or CRC, screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.